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INTRODUCTION
Every contraceptive method has advantages and
disadvantages. The advantages of implant are high
effectiveness, long-term usage, convenient usage,
minimal maintenance, quickly returned after
releasing the implant, minimal metabolic effects,
and relatively low cost. Limitations of the implant
are menstrual disorders, requiring surgical proce-
dures for insertion and removal, and no pro-
viding of protection against sexually transmitted
infections. The side effects are the main reason that
women stop using implants. The side effects
include irregular or prolonged bleeding, headaches,
mood swings, weight gain, depression or anxiety,
acne, abdominal discomfort, and pain in the area
of insertion.1-8
Abstract
Objective: To determine the effectiveness, safety, and time of
insertion between Monoplant® with Indoplant® to prevent preg-
nancy.
Methods: Data were collected from November 2015 until May 2016
in Raden Saleh Clinic. A total of 153 patients met the inclusion and
exclusion criteria for the study and were divided into 77 patients
who received Monoplant® and 76 patients received Indoplant®.
The study period was 6 months.
Results: The data obtained showed no significant difference in the
effectiveness of both contraceptive methods. In addition, side effects
such as menstrual disorders and weight gain did not differ signifi-
cantly in those study groups. However, the time of insertion between
Monoplant® and Indoplant® was siginificantly different (162.91 +
197.04 + 49.81 seconds versus 44.96 seconds, p<0.001). For compli-
cations such as skin irritation, inflammation, there are no differences
between Monoplant® (0.0%) and Indoplant® users (0.0%).
Conclusion: There are no significant differences in efficacy and
side effects using Monoplant® and Indoplant® during the 6-month
follow-up. However, the insertion time of Monoplant® is shorter
compared to Indoplant®’s. Monoplant® can be considered for use
as contraception with the effectiveness and side effects are almost
the same, but with shorter time of insertion compared to Indo-
plant®.
[Indones J Obstet Gynecol 2017; 5-2: 94-98]
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Abstrak
Tujuan: Untuk mengetahui efektivitas, keamanan penggunaan,
dan waktu penyisipan antara Monoplant® dibandingkan de-ngan Indoplant® untuk mencegah kehamilan.
Metode: Pengambilan data dilakukan sejak November 2015 hinggaMei 2016 di Klinik Raden Saleh. Sebanyak 153 pasien memenuhi
kriteria inklusi dan eksklusi penelitian dan dibagi menjadi 77 pasien
yang menerima susuk Monoplant® dan 76 pasien menerima susukIndoplant®. Penelitian dilakukan secara kohort prospektif hingga
observasi selama 6 bulan.
Hasil: Data yang didapat menunjukkan tidak terdapat perbedaan
bermakna pada efektivitas yaitu kejadian hamil pada penggunaanMonoplant® dan Indoplant®. Selain itu, efek samping seperti gang-
guan haid dan kenaikan berat badan tidak berbeda bermakna pada
kedua kelompok penelitian. Namun, waktu penyisipan antaraMonoplant® dan penyisipan Indoplant® (162,91 + 49,81 detik vs
197,04 + 44,96 detik, p<0,001) berbeda secara berkmakna. Untukkomplikasi sepert iritasi kulit, peradangan, tidak terdapat perbe-
daan komplikasi pada saat penyisipan Monoplant® (0,0%), dan
Indoplant® (0,0%).
Kesimpulan: Tidak terdapat perbedaan bermakna pada efektivitas
serta efek samping pada penggunaan Monoplant® dan Indoplant®selama 6 bulan follow-up. Namun, waktu penyisipan lebih singkat
untuk penggunaan Monoplant® dibandingkan Indoplant®. Dapatdipertimbangkan untuk menggunakan Monoplant® sebagai implan
untuk kontrasepsi dengan efektifitas dan efek samping yang hampir
sama, namun waktu penyisipan yang lebih singkat dibandingIndoplant®.
[Maj Obstet Ginekol Indones 2017; 5-2: 94-98]
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Indoplant® has already been marketed in
Indonesia since 2005 and gets good response
among family planning users in Indonesia. Indo-
plant®, consistsed of two rods, is reported to have
an effective and safe contraceptive based on
research.9 Monoplant® is a contraceptive implant
containing the same hormonal content as
Norplant® but have different packaging because it
consists only one rod. Monoplant® is expected to
be one of the more desirable contraceptive method
because the packaging is simpler which is expected
easier insertion and removal. Therefore, it is
needed to study further about comparison of the
effectiveness and safety of new contraceptive
implant that consists of one rod, which is
Monoplant®, with Indoplant®.
From the background, it can be formulated
whether there are differences in effectiveness,
safety, and the time of insertion between
Monoplant® compared with Indoplant®. This
study aims to determine the effectiveness, safety,
and time of insertion between Monoplant® with
Indoplant® to prevent pregnancy.
METHODS
A double-blind randomized clinical trial was used.
The affordable population were implant acceptors
in Family Planning Clinic, RSUPN Dr. Cipto
Mangunkusumo from August 1st, 2015 until
August 31st, 2018. Inclusion criteria of this study
were reproductive age women between 20 and 35
years, healthy, not in a pregnant, had active sexual
intercourse, not used hormonal contraception
within 6 months, explained and signed informed
consent, were willing to do repetitive visits, and
were only using implant as a contraceptive during
the three years period of study. Exclusion criteria
were having a family history of any type of
cancer, abnormal uterine bleeding, cardiovascular
problem, mental disorders, tuberculosis, frequent
headaches, history of liver disease or active liver
disease, using drugs that induce liver enzymes,
having high blood pressure, and severe hirsutism.
Data were collected using consecutive sampling.
If the corresponding patients were available,
they would be recruited as a research subject.
Processing and data analysis were performed using
the software "SPSS for Windows" version 20.0.
RESULTS
After the data were collected prospectively in
Obstetrics and Gynecology clinic, RSCM, we ob-
tained 153 subjects with 77 subjects of Mono-
plant® and 76 subjects of Indoplant®. At 1-month
follow-up, there were three subjects that is loss-to-
follow-up and 16 subjects had not yet reached the
period of 1 month during the study period. At 3-
month follow-up, there were two subjects who
dropped out of the study because they developed
intolerable side effects including drastic weight
gain and continuous spotting. At 6-month follow-
up, there were four subjects that can be assessed
when writing this report. Characteristics of the
subjects are presented in Table 1.
Table 1. Characteristics of the Subjects
Characteristics Monoplant® (n=77) Indoplant® (n=76)
Age 18-19 years old 0 (0.0) 1 (1.3)
20-24 years old 15 (19.5) 15 (19.7)
25-29 years old 22 (28.6) 26 (34.2)
30-34 years old 35 (45.5) 28 (36.8)
35-40 years old 5 (6.5) 6 (7.9)
Weight (kg) 58.78  11.59 56.99  12.52
Height (cm) 155.31  6.42 154.93  5.25
BMI (kg/m2) 24.37  4.57 23.70  4.74
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Normal distribution of data presented in mean
 standard deviations; abnormal distribution data
presented in median (minimum - maximum);
categorical data are presented in the amount
(percentage).
From these results, the most common of last
contraceptive method used by both groups as
much as 34 subjects (44.2 %).
The effectiveness of a contraception assessed
through the ability to prevent pregnancy. In both
groups of the study, the subjects assessed as preg-
nant or suspected pregnant. The result of the
analysis are shown in Table 2.
Characteristics Monoplant® (n=77) Indoplant® (n=76)
Blood pressure (mmHg) Systolic 115.06  12.51 116.47  14.45
Diastolic 75.90  9.43 75.64  10.71
Parity P0 2 (2.6) 0 (0.0)
P1 21 (27.3) 25 (32.9)
P2 34 (44.2) 30 (39.5)
P3 15 (19.5) 20 (26.3)
P4 3 (3.9) 0 (0.0)
> P4 2 (2.6) 1 (1.3)
Length of menstruation < 3 days 0 (0.7) 1 (1.3)
3-7 days 73 (94.8) 72 (94.7)
> 7 days 4 (5.2) 3 (3.9)
Lactation No 40 (51.9) 36 (47.4)
Yes 37 (48.1) 40 (52.9)
Last contraceptive method Pill 14 (18.2) 13 (17.1)
Implant 6 (7.8) 12 (15.8)
Injection 34 (44.2) 30 (39.5)
IUD 3 (3.9) 2 (2.6)
Condom/diaphragma 0 (0.0) 2 (2.6)
Withdrawal 0 (0.0) 0 (0.0)
Lactational amenorrhea
method (LAM) 3 (3.9) 2 (2.6)
Never 17 (22.1) 15 (19.7)
Table 2. Comparison of Effectiveness between Monoplant® and Indoplant®
Follow­up Research group N Pregnant or suspected pregnant p value
Yes No
1 month Monoplant® 69 0 (0.0) 69 (100.0) -*
Indoplant® 68 0 (0.0) 68 (100.0)
3 months Monoplant® 32 0 (0.0) 32 (100.0) -*
Indoplant® 30 0 (0.0) 30 (100.0)
6 months Monoplant® 1 0 (0.0) 1 (100.0) -*
Indoplant® 3 0 (0.0) 3 (100.0)
* Chi-Square test can not be conducted because the result of variable dependent is only 1 category
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Weight of the subjects were assessed at the
beginning of the implant insertion, 1 month, 3
months, and 6 months follow-up. The number of
subjects who reached 1-month follow-up was 35
subjects for Monoplant® and 37 subjects for
Indoplant®. Both group had increments in body
weight, ie 0.85 kg for Monoplant® and 0.5 kg to
Indoplant®. For the 3-month follow-up, insertion
of 1 and 3 months of Monoplant®, there were
increments of 0.27 kg and 0.57 kg from initial body
weight. After the insertion of 1 month and 3
months of Indoplant®, weight tended to be stable.
In four subjects who had reached the 6-month
follow-up, one Monoplant® subject gained 0.5 kg
since the use of the implant and stable 3 months
onward. For three Indoplant® subjects, two of
which gained 2 kg and 1 subjects gained 1 kg. It
should be noted that there was one Monoplant®
subject who dropped our study because she gained
11 kg in one month. The average weight gained in
3000 acceptors in China that used Norplant® was
2.5 kg.11 Within three years of usage of LNG
implant, the mean weight changed as much as 0.6
to 0.8 kg, of which 49.6 and 52.2% women in the
study had gain 1 kg or more, while 29.5 and 29.7%
decreased body of 1 kg or more.12
At the time of follow-up, menstrual disorders of
both groups of the study were assessed. The result
of the analysis is shown in Table 3.
Insertion time between Monoplant® and
Indoplant® were assessed. The insertion time for
Monoplant® and Indoplant® is 162.91  49.81
seconds and 197.04  44.96 seconds consecutively.
This difference is significant based on statistical
test (p value <0.001). At the time of insertion,
complications were also assessed. The results
showed no complications such as skin irritation,
infection, inflammation, or anaphylactic reaction in
Monoplant® (0.0%) and Indoplant® (0.0%).
DISCUSSION
Table 2 suggested that there was no contraceptive
failure at Monoplant® group (0.0%) and Indo-
plant® (0.0%). Thus, it can be concluded that there
is no difference in effectiveness between Indo-
plant® and Monoplant®. Another studies showed
that there were two Indoplant® subjects (0.7%)
who experienced pregnancy during 36 months9
and no pregnancy found in 30 Monoplant®
subjects at 6 months follow-up.10
Table 3. Comparison of Menstrual Disorders in Monoplant® and Indoplant®
Follow­up Characteristics Monoplant® Indoplant® p value
1 month Dismenorrhea Yes 6 (8.7) 24 (2.9) 0.274
No 63 (91.3) 30 (97.1)
Menstruation Amenorrhea 26 (37.7) 27 (39.7) 0.931
Shorter than usual 9 (13.0) 8 (11.8)
Normal/usual 21 (30.4) 18 (26.5)
Longer than usual 13 (18.8) 15 (22.1)
3 months Dismenorrhea Yes 1 (3.1) 0 (0.0) 1.000a
No 31 (96.9) 30 (100.0)
Menstruation Amenorrhea 9 (28.1) 10 (33.3) 0.937b
Shorter than usual 3 (9.4) 3 (10.0)
Normal/usual 8 (25.0) 8 (26.7)
Longer than usual 12 (37.5) 9 (30.0)
6 months Dismenorrhea Yes 0 (0.0) 0 (0.0) -*
No 1 (100.0) 3 (100.0)
Menstruation Amenorrhea 1 (100.0) 1 (33.3) 1.000
Shorter than usual 0 (0.0) 0 (0.0)
Normal/usual 0 (0.0) 2 (66.6)
Longer than usual 0 (0.0) 0 (0.0)
aT-dependent test, bFisher test, *Chi-Square test can not be conducted because the result of variable dependent is only 1 category
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There were no differences in menstrual dis-
orders between Monoplant® and Indoplant® at 1,
3, and 6 months follow-up. In addition, there was
one subject using Monoplant® who dropped out
due to exessive spotting. In both groups, there
were increased percentage of subjects with longer
menstrual duration. This is contrast with a study
conducted by Affandi B9 in Indonesia which
compared Norplant® and Indoplant®. It is reported
that were an increment in the percentage of
subjects with shorter periods than usual from the
beginning, 12, 24, and 36 months follow-up. This
may occur due to differences in measurement time
in our study, where the follow-up were conducted
at 1, 3, and 6 months, while Affandi B9 are at 12,
24, and 36 months.
CONCLUSION
Both implant have the same effectiveness, safety,
no differences in weight gain and menstrual dis-
orders during 1, 3, and 6 months follow-up.
However, the insertion of Monoplant® are faster
than Indoplant®. Monoplant® can be used as a
contraceptive method with the same effectiveness
and safety as Indoplant®, yet with shorter in-
sertion time.
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